Clinical Trials

Inclusion Criteria:

• Histologically confirmed diagnosis of multiple myeloma.
• Previous exposure to at least one PI, one IMiD and a CD38 antibody or has evidence of High-risk multiple myeloma (Defined as R-ISS III, relapsed or progressive disease within 12 months of initiating therapy, or presence of HR fish/genetics (Appendix III)). AND
  • Patient has received or will soon receive treatment with a novel immunotherapy.
• Eligible immunotherapies include:
  • BCMA targeted cellular therapy including chimeric antigen receptor Tcells (CAR T-cells).;
  • BCMA targeted antibody-drug conjugate therapy (ADC);
  • BCMA targeted immune cell engaging antibody (IEA);
  • Novel target (i.e. GPRC5D) directed CAR T-cell or other cellular therapy, ADC or IEA therapy;
  • Complete diagnostic and myeloma treatment data, pre-treatment variables and immunotherapy treatment details should be available (or be expected to be available) including safety, response and outcome assessments.
• Eligibility for control patients – is similar to immunotherapy subjects except that these patients have not received a novel immunotherapy.
  • At least three prior lines of therapy including a PI, IMiD and CD38 antibody;
  • Eligible to receive a novel immunotherapy but received other standard of care. therapy and data available to assess toxicity and response.
• Eligibility for VTB patients – is identical to the immunotherapy database eligibility but these subjects will have donated tissue samples as part of a separate local tissue-bank approved protocol, and patients must elect to allow the use of their data.
• Signed informed consent and access to the patient’s medical record is required.

Exclusion Criteria: 

• Any condition that, per investigator, would limit the ability for prospective chart review and data capture.
• Receipt of an immunotherapeutic regimen in a clinical trial that prohibits data sharing.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/2/2022. Questions regarding updates should be directed to the study team contact.